Drug Trial Radar · NCT04470427
A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19
Last checked: Nov 19, 2026Latest source record: Mar 21, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
30,415
Actual
Start
Jul 27, 2020
Primary completion
Dec 29, 2022
Study completion Dec 29, 2022
Sponsor
- Lead sponsor
- ModernaTX, Inc.Moderna (MRNA)
- Sponsor type
- Industry
- Collaborators
- Biomedical Advanced Research and Development Authority; National Institute of Allergy and Infectious Diseases (NIAID)
- First posted
- Jul 14, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The mRNA-1273 vaccine is being developed to prevent COVID-19, the disease resulting from Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) infection. The study is designed to primarily evaluate the efficacy, safety, and immunogenicity of mRNA-1273 to prevent COVID-19 for up to 2 years after the second dose of mRNA-1273.
Conditions
- SARS-CoV-2
Interventions
mRNA-1273Biological
Sterile liquid for injection
PlaceboBiological
0.9% sodium chloride (normal saline) injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Number of Participants With a First Occurrence of COVID-19 Starting 14 Days After Second DoseTime frame: From Day 43 (14 days after second dose) up to approximately 7 months after the second dose
- Part A: Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs) After First DoseTime frame: up to Day 7 (7 days after first dose)
- Part A: Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs) After Second DoseTime frame: Day 29 to Day 35 (from second dose to 7 days after second dose)
- Parts A and B: Number of Participants With Medically Attended AEs (MAAEs) and AEs Leading to DiscontinuationTime frame: Day 1 (after dosing) through end of study (up to Day 759)
- Parts A and B: Number of Participants With Serious AEs (SAEs)Time frame: Day 1 (after dosing) through end of study (up to Day 759)
Locations
100 sites in 1 country. Site status is shown where the registry gives one.
Ascension St. Vincent Birmingham
Birmingham, Alabama
Synexus Clinical Research US, Inc. - Birmingham
Birmingham, Alabama
Hope Research Institute
Chandler, Arizona
Synexus Clinical Research US, Inc. - Phoenix West
Glendale, Arizona
Hope Research Institute
Peoria, Arizona
Hope Research Institute
Phoenix, Arizona
Quality of Life Medical and Research Center
Tucson, Arizona
Baptist Health Center for Clinical Research
Little Rock, Arkansas
Advanced Clinical Research - Rancho Paseo
Banning, California
University of California San Diego
La Jolla, California
eStudySite - La Mesa
La Mesa, California
UCLA Vine Street Clinic CRS
Los Angeles, California
VA Greater Los Angeles Healthcare (veterans only)
Los Angeles, California
Paradigm Clinical Research Institute Inc
Redding, California
Benchmark Research - Sacramento
Sacramento, California
Medical Center For Clinical Research - M3 Wake Research
San Diego, California
University of Colorado Hospital
Aurora, Colorado
Lynn Institute of The Rockies
Colorado Springs, Colorado
George Washington University
Washington D.C., District of Columbia
Accel Research Site
DeLand, Florida
Research Centers of America
Hollywood, Florida
Jacksonville Center for Clinical Research
Jacksonville, Florida
Synexus - Optimal Research - Melbourne
Melbourne, Florida
Suncoast Research Group
Miami, Florida
University of Miami
Miami, Florida
Synexus Clinical Research US, Inc. - Orlando
Orlando, Florida
Palm Beach Research Center
West Palm Beach, Florida
Grady Health System
Atlanta, Georgia
Children's Healthcare of Atlanta
Atlanta, Georgia
Hope Clinic of The Emory Vaccine Center
Decatur, Georgia
Meridian Clinical Research
Savannah, Georgia
Clinical Research Atlanta
Stockbridge, Georgia
Synexus Clinical Research US, Inc. - Chicago
Chicago, Illinois
UIC Project WISH CRS
Chicago, Illinois
University of Chicago-Hospital
Chicago, Illinois
Johnson County Clin-Trials
Lenexa, Kansas
Alliance for Multispecialty Research
Newton, Kansas
Alliance for Multispecialty Research- East Wichita
Wichita, Kansas
Meridian Clinical Research
Baton Rouge, Louisiana
Benchmark Research - Metairie
Metairie, Louisiana
Showing 40 of 100 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.